Search All Research Studies
AHRQ Research Studies Date
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a monthly compilation of research articles funded by AHRQ or authored by AHRQ researchers and recently published in journals or newsletters.
Results1 to 5 of 5 Research Studies Displayed
Geynisman DM, Chien CR, Smieliauskas F
Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.
The researchers performed a comprehensive literature review of cost and cost-effectiveness research on therapeutic cancer vaccines and monoclonal antibodies, to better understand the economic impacts of these treatments. They discussed the implications surrounding the economic factors involved in cancer immunotherapies and suggested that further research on cost and cost-effectiveness of newer cancer vaccines and immunotherapies were warranted as this is a rapidly growing field with many new drugs on the horizon.
Citation: Geynisman DM, Chien CR, Smieliauskas F . Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review. Hum Vaccin Immunother 2014;10(11):3415-24. doi: 10.4161/hv.29407.
Keywords: Cancer, Healthcare Costs, Vaccination, Value
de Souza JA, Santana IA, de Castro Jr G
Economic analyses in squamous cell carcinoma of the head and neck: a review of the literature from a clinical perspective.
This review aims to evaluate the current literature related to economic analyses of treatment modalities for squamous cell cancer of the head and neck. The variation in findings among the studies reviewed demonstrates the challenges of performing economic analyses in a disease that requires an evolving and complex multidisciplinary approach.
Citation: de Souza JA, Santana IA, de Castro Jr G . Economic analyses in squamous cell carcinoma of the head and neck: a review of the literature from a clinical perspective. Int J Radiat Oncol Biol Phys. 2014 Aug 1;89(5):989-96. doi: 10.1016/j.ijrobp.2014.03.040..
Keywords: Cancer, Healthcare Costs, Value
Smieliauskas F, Chien CR, Shen C
Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review.
The researchers’ objective was to perform the first comprehensive review of cost-effectiveness analyses of targeted oral anti-cancer medications (OAMs). They concluded that in over half of the treatment settings in which a targeted OAM was compared with treatment that was not a targeted OAM, targeted OAMs were considered cost-effective.
Citation: Smieliauskas F, Chien CR, Shen C . Cost-effectiveness analyses of targeted oral anti-cancer drugs: a systematic review. Pharmacoeconomics 2014 Jul;32(7):651-80. doi: 10.1007/s40273-014-0160-z..
Keywords: Value, Healthcare Costs, Medication, Cancer
Ekwueme DU, Yabroff KR, Guy GP, Jr.
AHRQ Author: Soni A, Davidoff A
Medical costs and productivity losses of cancer survivors--United States, 2008-2011.
In order to estimate annual medical costs and productivity losses among male and female cancer survivors and persons without a cancer history, the CDC, along with other organizations, analyzed data from the 2008-2011 Medical Expenditure Panel Survey (MEPS) and found that the economic burden of cancer survivorship is substantial among all survivors. These findings identified a need to develop and evaluate health and employment intervention programs aimed at improving outcomes for cancer survivors and their families.
Citation: Ekwueme DU, Yabroff KR, Guy GP, Jr. . Medical costs and productivity losses of cancer survivors--United States, 2008-2011. MMWR Morb Mortal Wkly Rep 2014 Jun 13;63(23):505-10.
Keywords: Cancer, Healthcare Costs, Medical Expenditure Panel Survey (MEPS)
Huo J, Lairson DR, Du XL
Survival and cost-effectiveness of hospice care for metastatic melanoma patients.
The authors analyzed the association of hospice use with survival and health care costs among patients diagnosed with metastatic melanoma. They found that the median survival time was 6.1 months for patients with no hospice care, 6.5 months for patients enrolled in hospice for 1 to 3 days, and 10.2 months for patients enrolled for 4 or more days. Patients with 4 or more days of hospice care incurred lower end-of-life costs than the comparison groups.
Citation: Huo J, Lairson DR, Du XL . Survival and cost-effectiveness of hospice care for metastatic melanoma patients. Am J Manag Care 2014 May;20(5):366-73.
Keywords: Cancer, Cancer: Skin Cancer, Healthcare Costs, Palliative Care, Patient-Centered Outcomes Research